Our
Biology business, which grew by 3%, delivered overall as expected, showing
moderate growth for our core Biomolecule an synthetic DNA business. The
innovative and faster growing areas of our Biology business, which includes our
zinc finger nuclease products, continue delivering double-digit growth in the
first quarter, as we continue to invest in initiatives that are broadening the
availability and breadth of our zinc finger offering to a wider group of
customers through new and innovative applications.
From Q&A:
Daniel Arias - UBS Investment Bank, Research Division
Okay. And I'm not sure if I missed it. You guys have highlighted
zinc finger over the last couple of quarters and certainly that was one of the
focus at the investor day. Just wondering how that product line performed?
Rakesh Sachdev
We had an all-time high on zinc finger sales in the U.S. in Q1.
It was -- I don't have the numbers at the tip of my fingers, but I think it
grew at least 30%. So it's really where we are seeing the most growth around
the zinc fingers is in the U.S. market and we're hoping to sort of replicate
that in the European markets, although I would say there it's been a little
slower than the U.S.
